Kerim Margaret Babaoglu

US Patent:

20120003215, Jan 5, 2012

Filed:

Jun 23, 2011

Appl. No.:

13/167618

Inventors:

Kerim Babaoglu - Pacifica CA, US
Constantine G. Boojamra - San Francisco CA, US
Eugene J. Eisenberg - San Carlos CA, US
Hon Chung Hui - San Mateo CA, US
Richard L. Mackman - Milbrae CA, US
Jay P. Parrish - Redwood City CA, US
Michael Sangi - , US
Oliver L. Saunders - San Mateo CA, US
Dustin Siegel - Foster City CA, US
David Sperandio - Palo Alto CA, US
Hai Yang - San Mateo CA, US

Assignee:

Gilead Sciences, Inc. - Foster City CA

International Classification:

A61K 31/519
C07D 413/14
A61P 31/14
A61K 31/7056
A61K 39/42
C07D 487/04
A61K 31/5377

US Classification:

4241331, 544281, 544117, 540575, 5142593, 5142332, 51421021, 514 43

Abstract:

The invention provides compounds of Formula I or Formula II:or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

US Patent:

20130203727, Aug 8, 2013

Filed:

Jul 1, 2011

Appl. No.:

13/806067

Inventors:

Kerim Babaoglu - Lansdale PA, US
Elizabeth Bacon - Burlingame CA, US
Kyla Bjornson - San Mateo CA, US
Hongyan Guo - San Mateo CA, US
Randall L. Halcomb - Foster City CA, US
Paul Hrvatin - South San Francisco CA, US
John O. Link - San Francisco CA, US
Hongtao Liu - Cupertino CA, US
Ryan McFadden - Foster City CA, US
Michael L. Mitchell - Hayward CA, US
Paul Roethle - San Francisco CA, US
James Taylor - San Mateo CA, US
James D. Trenkle - Oakland CA, US
Randall W. Vivian - San Mateo CA, US
Lianhong Xu - Palo Alto CA, US

Assignee:

GILEAD SCIENCES, INC. - Foster City CA

International Classification:

C07C 59/64
C07D 491/06
C07D 205/04
C07D 239/34
C07D 295/155
C07C 311/16
C07C 255/57
C07C 229/34
C07D 213/65
C07D 239/26
C07D 231/12
C07D 487/04
C07D 211/48
C07D 309/10
C07D 311/58
C07C 233/47
C07C 271/22
C07D 239/42
C07D 239/36
C07D 215/14

US Classification:

51421001, 562466, 546173, 514569, 514311, 546 89, 514291, 548950, 544298, 514269, 544171, 5142392, 562430, 514562, 558414, 514510, 562451, 546302, 514345, 514567, 544335, 514256, 546342, 514406, 5483771, 544350, 514249, 546205, 514319, 549416, 514460, 549398, 514456, 514563, 514481, 560 28, 514277, 544332, 514275, 544318, 514274

Abstract:

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).

US Patent:

20130210801, Aug 15, 2013

Filed:

Jul 1, 2011

Appl. No.:

13/806048

Inventors:

Kerim Babaoglu - Lansdale PA, US
Kyla Bjornson - San Mateo CA, US
Hongyan Guo - San Mateo CA, US
Randall L. Halcomb - Foster City CA, US
John O. Link - San Francisco CA, US
Hongtao Liu - Cupertino CA, US
Michael L. Mitchell - Hayward CA, US
Jianyu Sun - Burnaby, CA
James Taylor - San Mateo CA, US
Randall W. Vivian - San Mateo CA, US
Lianhong Xu - Palo Alto CA, US

Assignee:

GILEAD SCIENCES, INC. - Foster City CA

International Classification:

C07D 498/04
C07D 215/48
C07D 491/052
C07D 215/14

US Classification:

51421021, 546173, 514311, 514314, 546170, 546169, 546 89, 514291, 544128, 5142352, 544105, 5142305, 544101, 5142302

Abstract:

The invention provides compounds of formula (I): or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula (I), processes for preparing compounds of formula (I), intermediates useful for preparing compounds of formula I and therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds of formula (I).

US Patent:

20190314486, Oct 17, 2019

Filed:

Oct 18, 2017

Appl. No.:

16/343272

Inventors:

- Rahway NJ, US
Lan Zhang - Chalfont PA, US
Kerim Babaoglu - Lansdale PA, US
Arthur Fridman - East Norriton PA, US
David Nickle - Seattle WA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 39/145
A61P 31/16
C07K 14/11

Abstract:

The disclosure relates to influenza virus hemagglutinin protein and DNA vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

US Patent:

20180311336, Nov 1, 2018

Filed:

Oct 21, 2016

Appl. No.:

15/767609

Inventors:

- Cambridge MA, US
Eric Yi-Chun Huang - Boston MA, US
Kerim Babaoglu - Lansdale PA, US
Jessica Ann Flynn - Lansdale PA, US
Lan Zhang - Chalfont PA, US

Assignee:

Moderna TX, Inc. - Cambridge MA

International Classification:

A61K 39/145

Abstract:

The disclosure relates to influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.

US Patent:

20170305923, Oct 26, 2017

Filed:

Jun 9, 2014

Appl. No.:

14/895613

Inventors:

- Rahway NJ, US
John M. Sanders - Collegeville PA, US
Kerim Babaoglu - Lansdale PA, US
Abbas Walji - Lansdale PA, US
John S. Wai - Harleysville PA, US
Paul J. Coleman - Harleysville PA, US

Assignee:

MERCK SHARP & DOHME CORP. - Rahway NJ

International Classification:

C07D 487/14
A61K 45/06
A61K 31/4985
A61K 31/5383
C07D 498/14
C07D 491/048

Abstract:

The present invention relates to Fused Tricyclic Heterocycle Derivatives of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, X, Y, m, R1, R5, Ra and Rb are as defined herein. The present invention also relates to compositions comprising at least one Fused Tricyclic Heterocycle Derivative, and methods of using the Fused Tricyclic Heterocycle Derivatives for treating or preventing HIV infection in a subject.

US Patent:

20170114071, Apr 27, 2017

Filed:

Mar 23, 2015

Appl. No.:

15/128689

Inventors:

- Rahway NJ, US
- Shanghai, CN
Andrew J. Cooke - West Point PA, US
Craig A. Stump - West Point PA, US
Casey C. McComas - Phoenixville PA, US
Kathy Schirripa - Quakertown PA, US
Melody McWherter - Boyertown PA, US
Swati P. Mercer - Philadelphia PA, US
Kerim Babaoglu - Lansdale PA, US
Dongfang Meng - Morganville NJ, US
Jane Wu - Marlboro NJ, US
Ping Liu - Westfield NJ, US
Harold B. Wood - Westfield NJ, US
Jianming Bao - Shanghai, CN
Chun Sing Li - Shanghai, CN
Qinghua Mao - Shanghai, CN
Zhiqi Qi - Shanghai, CN

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
MSD R & D (China) Co., LTD. - Shanghai

International Classification:

C07D 491/107
C07D 403/12
C07D 401/12
C07C 233/66
C07D 417/12
C07D 239/42
C07D 401/04
C07D 413/12
C07D 417/14
C07D 401/14
C07D 405/12
C07D 413/14
C07D 403/14
C07D 405/14
C07D 471/04
C07D 401/06
C07D 413/06
C07D 403/06
C07D 213/75

Abstract:

The present invention is directed to six membered heteroaryl benzamide compounds of formula (I), which are tropomyosin-related kinase (Trk) family protein pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor TrkA.